Physiological effects of roflumilast at rest and during exercise in COPD

European Respiratory Journal

Volumn 39, Issue 5, 2012, Pages 1104-1112

  O'Donnell, Denis E ^a   Bredenbröker, Dirk ^b   Brose, Manja ^b   Webb, Katherine A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b Nycomed GmbH   (Germany)

Author keywords

Anti inflammatory; Chronic obstructive pulmonary disease; Exercise; Phosphodiesterase 4 inhibitor

Indexed keywords

PLACEBO; ROFLUMILAST; SALBUTAMOL;

ADULT; AIRWAY RESISTANCE; ANXIETY; ARTERIAL OXYGEN SATURATION; ARTICLE; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; GASTROINTESTINAL DISEASE; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PATIENT COMPLIANCE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SPIROMETRY; WEIGHT REDUCTION; XEROSTOMIA;

AGED; AIRWAY RESISTANCE; AMINOPYRIDINES; BENZAMIDES; BRONCHODILATOR AGENTS; CYCLOPROPANES; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PHYSICAL ENDURANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; REST; SEVERITY OF ILLNESS INDEX;

EID: 84860473468     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00096511     Document Type: Article

References (29)

1. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
2. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
3. Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
4. Calverley PMA, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154-161. (Pubitemid 47057851)
5. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-571. (Pubitemid 41140331)
6. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953. (Pubitemid 29288270)
7. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823. (Pubitemid 29251012)
8. Grootendorst DC, Gauw SA, Baan R, et al. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm Pharmacol Ther 2003; 16: 115-120. (Pubitemid 36369401)
9. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840. (Pubitemid 38807355)
10. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94. (Pubitemid 39029073)
11. Haverkamp HC, Dempsey JA, Pegelow, DF., et al. Treatment of airway inflammation improves exercise pulmonary gas exchange and performance in asthmatic subjects. J Allergy Clin Immunol 2007; 120: 39-47. (Pubitemid 46990485)
12. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276. (Pubitemid 32378468)
13. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758. (Pubitemid 14121920)
14. American Thoracic Society. Standardization of spirometry - 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
15. Coates AL, Peslin R, Rodenstein D, et al. Measurement of lung volumes by plethysmography. Eur Respir J 1997; 10: 1415-1427. (Pubitemid 27278270)
16. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
17. Briscoe WA, Dubois AB. The relationship between airway resistance, airway conductance and lung volume in subjects of different age and body size. J Clin Invest 1958; 37: 1279-1285.
18. Cotes JE, Chinn DJ, Quanjer PH, et al. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 41-52.
19. Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381. (Pubitemid 13215050)
20. Jones NJ. Clinical exercise testing. Philadelphia, WB Saunders Company, 1988; pp. 306-307.
21. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050. (Pubitemid 34280421)
22. Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD 2010; 7: 428-437.
23. Rosenkranz MA, Busse WW, Johnstone T, et al. Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation. Proc Natl Acad Sci USA 2005; 102: 13319-13324. (Pubitemid 41325021)
24. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926-934. (Pubitemid 39258050)
25. Ottanelli R, Rosi E, Romagnoli I, et al. Do inhaled corticosteroids affect perception of dyspnea during bronchoconstriction in asthma? Chest 2001; 120: 770-777. (Pubitemid 32885448)
26. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in COPD. Am J Respir Crit Care Med 2001; 164: 770-777.
27. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol 2006; 101: 1025-1035. (Pubitemid 44497544)
28. Izziki M, Raffestin B, Klar J, et al. Effects of roflumilast, a phophodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats. J Pharmacol Experimental Therap 2009; 330: 54-62.
29. Hsai D, Casaburi R, Pradhan A, et al. Physiological responses to linear treadmill and cycle ergometer exercise in COPD. Eur Respir J 2009; 34: 605-615.